Abstrak
Gastroesophageal reflux is closely associated with many symptoms and disorders of airways including chronic cough and asthma.
3,4
Several studies showed that approximately 45-77% asthma patients had GERD symptoms. 5, 6 Endoscopic findings from asthma patients showed that oesophagitis prevalence in asthma patients approximately 27-43%.
4,7 A study with 24h pH monitor found abnormal acid reflux in 33-90% asthma patients. 6, 8 There were several factors in pathogenesis gastroesophageal reflux in asthma patients. Among others, there were autonomic dysregulation, increased pressured gradient between the thorax and the abdominal cavity, diaphragma cruralis dysfunction, hiatus hernia and used of asthma medications. Furthermore, gastroesophageal reflux induced bronchoconstriction in asthma patients by esophago-bronchial vagal reflex, increased bronchial reactivity and acid microaspiration into airways. 6, 9, 10 Another mechanism that may play a role is neurogenic inflammation (axon reflex) with tachykinin and P substance release in the airways. 6, 10 Management of GERD in asthma patients should be considered seriously to obtain optimal control of asthma. The role of GERD treatment in asthma control is still unclear. Antireflux medications did not show consistent result improving lung function, asthma symptoms, reducing night asthma or use of asthma medications in asthma patients. 1,9,11 A review by Bowrey et.al 9 stated several studies with antireflux treatment decreased asthma symptoms, decreased asthma medications but had minimal effect on lung function. The use of proton pump inhibitor (PPI) as drug of choice for GERD showed a better result than other antireflux drugs. 2, 6, 9 This study aimed to evaluate the effect of the latest generation proton pump inhibitor (esomeprazole) to reduce asthma symptoms, use of inhaled bronchodilator and increase peak expiratory flow rate (PEFR) in moderate persistent asthma with GERD. Patients were divided into 2 groups, the first group received esomeprazole treatment and the other without esomeprazole (control group). In each group was given standard treatment of moderate persistent asthma, which is budesonide inhalation 2 x 400 mg/day as a controller and salbutamol 100 mg/puff as a reliever. In each group the conservative treatment of GERD was given such as lifestyle modifications and antacid (if necessary).
METHODS
Duration of study was 14 weeks, divided into 2 weeks run in periode, 8 weeks treatment periode and 4 weeks wash out periode. In each periode there was daily evaluation for asthma symptoms, use of inhaled bronchodilator (β 2 agonist inhaled short acting), morning and evening PEFR and weekly evaluation for GERD symptoms. Scoring for asthma symptoms were cough, night sleep disturbance, activity disturbance and wheezing.
Asthma symptom total score is the total value of asthma symptoms score in one day. Scoring for GERD symptom is evaluated by diary card, through symptoms e.g. heartburn, atypical chest pain and regurgitation. GERD symptom total score is the total value of GERD symptoms score in one weeks. Statistical Program for Social Sciences (SPSS) 10 was used for data analysis. Parametric test is use if normally data distribution with multiple repeated measured analysis of variance (Anova) test to test variable by time of treatment (before, during, and after treatment) and comparison between the two groups. Nonparametric test is used if data distribution is abnormal. Friedmann test for test variable by time of treatment and Mann Whitney test or t test to evaluate comparative variable between the two groups at the same time, i.e. cough score, sleep disturbance etc.
Because the result is concluded from 2 tests, therefore significant statistic test used Bonnferoni correction. Differentiation between 2 qualitative data proportion used chi-square test. In parametric test value P < 0.05 is considered significantly different; and nonparametric test value P < 0.003125 is considered significantly different.
This study has been approved by Ethics Committee of the Faculty of Medicine University of Indonesia.
RESULTS
Out of 36 patients, four patients dropped out from this study: 2 patients from esomeprazole group (one patients resign and one patient with melena); and in control group 2 patients who did not continue after 4 weeks treatment, and one patients exacerbate that needed systemic corticosteroid. Therefore, a number of 32 patients moderate persistent asthma with GERD were finished this study, 16 patients in each group.
In esomeprazole group and control group (without esomeprazole) were similarly distributed in term of gender, age, height, body weight, history of asthma illness, lung function (FEV 1 %, FVC%, PEFR), and bronchial hyperreactivity (PC 20 higher compare to control group PEFR value, which was 5.9 L/minute. Night PEFR after 8 weeks in esomeprazole group was increased 26.8 L/minute higher than control group 9.2 L/minute. Comparison morning and night PEFR between two groups after 8 weeks treatment were not significantly difference (p > 0.003125).
administration was not different with other study -Roussos et al. 5 (42.9 + 14.2 year) also Talib et al.
15
(43.43+14.6 year). Baseline of lung function (not include VC) and bronchial hiperreactivity was equally distributed between two groups. The value support the diagnosis moderate persistent asthma in all patients that finished this study. GERD symptoms in asthma patients were not different with previous study by Roussos et al 5 and Nakase et al.
7
Our study showed that asthma patients with GERD symptoms proven to have had erosive oesophagitis was likely in accordance with Talib et al 15 which found 63.33% had erosive oesophagitis. Our result was higher than previous report that showed approximately 15-43%.
4,7 Our result was different from several previous studies because our patients were limited to asthma patients with GERD symptoms, however the other studies consisted of all asthma patients.
Total score of GERD symptoms in esomeprazole group decreased higher than control in each periode. In control group also improved GERD symptoms maybe caused patients still received conservative treatment for GERD. Conservative treatment alone for GERD could decreased reflux symptoms in asthma patients with GERD. 9 In this study, GERD treatment with esomeprazole improved asthma symptoms. This result was likely similar with the other findings 6 that agrresive medical therapy improved asthma symptoms in about 70% of asthmatic with GERD. In addition, our study revealed that total score of asthma symptoms were decreased 68.2% compared to baseline. This result was similar with study by Sharma 18 which used omeprazole 40mg/ daily for 8 weeks, found that daily asthma symptoms decreased significant. Moreover, Kiljander et.al 19 found improvement only in nighttime asthma symptoms with omeprazole 40 mg/daily. Previous studies using antisecretoy e.g. omeprazole did not consistently improve asthma symptoms.
11 Inferior result maybe caused by inadequate reflux control. A review by Bowrey et.al concluded that a success with medical treatment were likely to be related directly to eliminate reflux. The conflicting findings of antisecretory therapy may be due to the inadequate control gastroesophageal reflux.
8 Esomeprazole is newer generation of PPI drugs. Pharmacodinamic study result esomeprazole had activity acid suppresion higher than omeprazole.
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On the other hand, esomeprazole 40 mg/day showed controlled intragastric pH more than 4 (pH > 4) better and longer than omeprazole 20 mg/day.
21
The use of inhaled bronchodilator was significantly decreased compared to control. Several studies using antisecretory did not reduce the use of asthma medi cations. Several previous studies showed medical antireflux treatment could decrease use of asthma medications, However, other studies show contrary result.
11 Asthma symptoms in patients who received esomeprazole were decreased. This may cause decrease use of asthma medications (inhaled bron chodilator). Inhaled bronchodilator is a reliever in asthma medications on necessary basis that act quickly to relieve asthma symptoms.
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Morning and night PEFR improvement in esomeprazole group was higher than control. Most studies about role of antireflux treatment on asthma patients previously showed that antireflux treatment had minimal or no effect on PEFR. 6,9,11 A limited improvement of daily PEFR were found in several other studies. Tsugeno et al. 23 found PEFR improvement in only 38.1% of asthma patients with GERD. Nakase et al. 7 reported that improvement of morning PEFR and night PEFR were only in asthma patients who had erosive oesophagitis grade C/D. Kiljander et al. 24 using esomeprazole 20 mg twice daily showed improved PEFR only in asthma patients with GERD and nocturnal respiratory symptoms. There were several unknown factors contributed in successful improvement of PEFR.
CONCLUSION
Administration of esomeprazole 40 mg/day for 8 weeks improved asthma symptoms and decreased the use of inhaled bronchodilator in moderate persistent asthma patient with GERD.
